Search Results

30 posts

Recce Pharma heading closer to full efficacy data for flagship R327

Recce Pharma has announced the latest cohort of patients in the company's Phase I/II UTI trial…

Recce breathes better on positive lung infection drug pilot test results

Recce Pharmaceuticals Ltd has revealed positive results from its pilot test on synthetic drug Recce 327,…

Recce Pharma picks up Chinese patent for anti-infective drugs

Recce Pharmaceuticals (ASX:RCE) has confirmed its receipt of a patent in China to protect its class…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Recce weighs in on Q1 2024 as cash increases 100%

Recce Pharmaceuticals, developing a new body of anti-infectives for global markets, weighs in on the last…

Recce Pharmaceuticals up 6% on new antibiotic production milestone

Recce Pharmaceuticals (ASX:RCE) is trading up more than 6 per cent after producing a 5000-dose batch…
The Market Online Video

Recce gearing up for Indonesian trials; US DOD looking at R327 burn gel

Recce Pharmaceuticals published a business update highlighting two key developments with the potential to deliver share…

Recce Pharmaceuticals inks new patent for flagship drug in Israel

Recce Pharmaceuticals (ASX:RCE) has successfully obtained a patent for its flagship anti-infective drug R327 in Israel.

Recce Pharmaceuticals secures Trademark Registration in Canada

Recce Pharmaceuticals secures Trademark Registration in Canada for its antibiotics.
The Market Online Video

Recce reaches testing milestone for UTI, Uroseptis antibiotic

Recce Pharmaceuticals Limited (ASX: RCE) has completed tests involving a four-person cohort for its RECCE 327…

Recce Pharma (ASX:RCE) kicks-off dosing for next cohort of UTI trial

Recce Pharmaceuticals (ASX: RCE) has announced the successful dosing of the latest group of human participants…
The Market Online Video

Recce Pharmaceuticals secures AUD$11.18M from Endpoints Capital

Recce Pharmaceuticals (ASX:RCE, FSE:R9Q) has announced the receipt of an AUD$11,178,965 R&D Advance from Endpoints Capital.

Recce Pharmaceuticals leads the way in collaborative Anti-Infective research

Recce Pharmaceuticals (ASX:RCE) has announced the ongoing initiatives within its Anti-Infective Research (AIR) Unit situated at…

Recce Pharmaceuticals wins safety approval to expand wound infection trial

Recce Pharmaceuticals' (ASX:RCE) work in the diabetic post-surgery space is set to expand with a key…
The Market Online Video

Recce Pharmaceuticals teams with leading Indonesian biomed company for anti-infective push

Recce Pharmaceuticals (ASX:RCE) has inked an MOU with PT Etana Biotechnologies, a leading biomedical organisation in…

Recce Pharmaceuticals ends Q2 FY24 with $4m in cash; growing safety data

Recce Pharmaceuticals (ASX:RCE), developing a line of next-gen anti-infectives useful in the treatment of multiple conditions,…
The Market Online Video

Recce Pharmaceuticals to expand diabetes foot infection trial as results prove strong

Recce Pharmaceuticals (ASX:RCE) is seeking to expand internationally a key trial investigating the use of its…
The Market Online Video

Recce secures Australia’s largest-ever $11m Advanced Overseas R&D Finding

Recce Pharmaceuticals (ASX: RCE) has been awarded the largest R&D Tax rebate in Australian history from…

Recce Pharmaceuticals awarded $43.7m AusIndustry Advanced Overseas Finding

Recce Pharmaceuticals' (ASX:RCE) lead anti-infective drug, R327 has shown significant bacterial reduction against the life-threatening STD,…

Recce Pharmaceuticals wins Canadian patent for flagship anti-infectives

Recce Pharmaceuticals (ASX:RCE) has announced its receipt of a patent for its anti-infective drugs in Canada.